

reaction at 95°C for 1 minute and then amplified with 27 cycles of 98°C for 10 seconds, 60°C for 5 seconds, 72°C for 1 minute. This amplification was monitored on a T100 Thermal Cycler (Bio-Rad). The primers used are shown in Supplemental Tables 6 and 7.

Microarray analysis. HeLa cells were plated in a 6-cm culture dish at a density of 1×10^5 cells per dish. Cells were incubated with FIT-039 or flavopiridol at 4 μ M or 800 nM, respectively, following total RNA extraction using the RNeasy Mini Kit (QIAGEN), per the manufacturer's instructions. RNA was prepared for microarray expression analysis by the GeneChip 3' IVT Expression Kit (Affymetrix Inc.) according to the manufacturer's instructions. The prepared RNA was hybridized and stained onto the Human Genome U133 Plus 2.0 array (Affymetrix Inc.) using the GeneChip Hybridization Wash and Stain Kit (Affymetrix Inc.). Signals were detected using the GeneChip Scanner 3000G (Affymetrix Inc.). These data were analyzed with Perl scripts and a statistical package, R (<http://www.r-project.org/>).

Two-week repeat-dose oral toxicity study. Male 5-week-old Wister rats were purchased from Charles River Laboratories Inc. FIT-039 (1,000 mg/kg) or the solvent (carboxymethylcellulose) was administered orally to male rats once a day for 14 days, and these animals were followed for 14 days from the final administration. Three rats were assigned to each experimental group. Body weights and general conditions were determined for 28 days from the first administration. Hematology tests were performed and the organ weights were noted on day 28.

Ointment supplement with chemical compounds. The 5% ACV ointment, which contained polyethylene glycol, glycerol, and ACV, was provided by Rakool Pharmaceutical Marketing Co. Ltd. Japan. We used 10% lactic acid, in addition to polyethylene glycol and glycerol, to dissolve FIT-039 in ointment.

Mouse skin HSV-1 or ACV-resistant HSV-1 infection model. Male 5-week-old ICR mice were purchased from Charles River Laboratories Inc. The left mid-flank of each mouse was depilated with a chemical depilatory hair remover. The naked skin was scratched 1 or 2 days later with a 27-gauge needle, and 20 μ l of the HSV-1 suspension of 2×10^5 PFUs was applied to the scratched area. Each ointment was administered to mice (5 mice per group) as follows. For experiment 1 (topical treatment, the effect of different concentrations), FIT-039 prepared in the ointment formulation at concentrations of 1.25%, 2.5%, 5%, and 10% (w/w) was topically applied to the scratched area (30 mg/area/dose) 3 hours after the HSV-1 infection and twice daily for 12 days. For experiment 2 (topical treatment, therapeutic efficacy of FIT-039 in skin ACV-resistant HSV-1-infected mice), 10% FIT-039 ointment was applied topically to the scratched area (30 mg/area/dose) 3 hours after the ACV-resistant HSV-1 infection and twice daily for 12 days. The placebo (ointment base) and 5% ACV ointment applied twice daily were

used as control. In both experiments, the development of skin lesions and mortality were continuously observed twice daily for 12 days after the HSV-1 or ACV-resistant HSV-1 infection and scored as follows: 0, no lesion; 2, vesicles in a local region; 4, erosion and/or ulceration in a local region; 6, mild zosteriform lesion; 8, moderate zosteriform lesion; 10, severe zosteriform lesion; 14, death.

Database repository. Gene expression profiling data were deposited in GEO (accession no. GSE57429).

Statistics. Numerical values are reported as mean \pm SD unless stated otherwise. Statistical significance was determined with a 2-tailed Student's *t* test. A *P* value of less than 0.05 was considered significant.

Study approval. All animal protocols were reviewed and approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University.

Acknowledgments

We thank Kei Aoyama, Chikako Murasaki, and Takako Koike (Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology) for their contributions on the synthesis of small compounds; Ayako Hosoya (Tokyo Medical and Dental University) for HRMS analyses; Koki Aoki and Shigeaki Ohno (Department of Ophthalmology, Graduate School of Medicine, Hokkaido University) for ADV types 19, 37, and 53; Youich Kobayashi, Minoru Morita, Yuushin Akimoto, Shigeru Imoto, Yukihiko Shibuya, and Takuya Kato (Rakool Pharmaceutical Marketing Co. Ltd. Japan) for the FIT-039 ointment; Kenji Ooe for help writing the manuscript; and Yasushi Kawaguchi, Daisuke Watanabe, and our laboratory members for their critical comments and discussion. We also thank the Institute of Laboratory Animals Graduate School of Medicine and the Radioisotope Research Center of Kyoto University for their instrumental support. This work was supported by Grants-in-Aid for Scientific Research (21249013 to M. Hagiwara), Research Program of Innovative Cell Biology (231006 to M. Hagiwara), and Platform for Drug Discovery (to M. Hagiwara) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan and by grants from National Institute of Biomedical Innovation (241011 to M. Hagiwara), CREST (231038 to M. Hagiwara), and Risk-Taking Fund for Technology Development (D06-14 to KinoPharma Inc.) from Japan Science and Agency.

Address correspondence to: Masatoshi Hagiwara, Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku Kyoto, 606-8501 Japan. Phone: 81.75.753.4341; E-mail: hagiwara.masatoshi.8c@kyoto-u.ac.jp.

- Ostertag W, et al. Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. *Proc Natl Acad Sci U S A*. 1974;71(12):4980-4985.
- Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antihyperthermic agent, 9-(2-hydroxyethoxymethyl) guanine. *Proc Natl Acad Sci U S A*. 1977;74(12):5716-5720.
- Sellar RS, Peggs KS. Management of multi-drug-resistant viruses in the immunocompromised host. *Br J Haematol*. 2012;156(5):559-572.
- Field HJ. Herpes simplex virus antiviral drug resistance--current trends and future prospects. *J Clin Virol*. 2001;21(3):261-269.
- Wang Y, Wang Q, Zhu Q, Zhou R, Liu J, Peng T. Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children. *J Clin Virol*. 2011;52(2):107-112.
- Karlas A, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. *Nature*. 2010;463(7282):818-822.
- Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. *J Antimicrob Chemother*. 2002;50(6):779-792.
- Siakallis G, Spandidos DA, Sourvinos G. Herpesviridae and novel inhibitors. *Antivir Ther*. 2009; 14(8):1051-1064.
- Kusano-Kitazume A, et al. Identification of novel N-(morpholine-4-carboxyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. *Antimicrob Agents Chemother*. 2012;56(3):1315-1323.

10. Anwar A, et al. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly. *Plos One*. 2011;6(8):e23246.
11. Karakama Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. *Antimicrob Agents Chemother*. 2010;54(8):3179–3186.
12. Fukuhara T, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. *Proc Natl Acad Sci U S A*. 2006;103(30):11329–11333.
13. Van Duyn R, et al. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. *J Mol Biol*. 2013;425(4):812–829.
14. Kapasi AJ, Clark CL, Tran K, Spector DH. Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription. *J Virol*. 2009;83(11):5904–5917.
15. Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. *Antivir Chem Chemother*. 2006;17(6):293–320.
16. Tan SL, Ganji G, Paepfer B, Proll S, Katze MG. Systems biology and the host response to viral infection. *Nat Biotechnol*. 2007;25(12):1383–1389.
17. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer*. 2009;9(3):153–166.
18. Kohoutek J, Blazek D. Cyclin K goes with Cdk12 and Cdk13. *Cell Div*. 2012;7:12.
19. Evers DL, Breitenbach JM, Borysko KZ, Townsend LB, Drach JC. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity. *Antimicrob Agents Chemother*. 2002;46(8):2470–2476.
20. Feichtinger S, et al. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1. *J Gen Virol*. 2011;92(pt 7):1519–1531.
21. Rechter S, et al. Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. *J Biol Chem*. 2009;284(13):8605–8613.
22. Durand LO, Roizman B. Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. *J Virol*. 2008;82(21):10591–10599.
23. Biglione S, et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. *Retrovirology*. 2007;4:47.
24. Ou M, Sandri-Goldin RM. Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription. *Plos One*. 2013;8(10):e79007.
25. Meinhart A, Kamenski T, Hoepfner S, Baumli S, Cramer P. A structural perspective of CTD function. *Genes Dev*. 2005;19(12):1401–1415.
26. Sanchez V, et al. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL137 immediate-early transcripts and at later times for virus production. *J Virol*. 2004;78(20):11219–11232.
27. Schang LM, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. *J Virol*. 2002;76(15):7874–7882.
28. Delehouze C, et al. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells [published online ahead of print December 9, 2013]. *Oncogene*. doi:10.1038/onc.2013.513.
29. Thomas JP, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. *Cancer Chemother Pharmacol*. 2002;50(6):465–472.
30. Diwan P, Lacasse JJ, Schang LM. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. *J Virol*. 2004;78(17):9352–9365.
31. Simmons A, Nash AA. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. *J Virol*. 1984;52(3):816–821.
32. Betz UA, Fischer R, Kleymann G, Hendrix M, Rubsamens-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. *Antimicrob Agents Chemother*. 2002;46(6):1766–1772.
33. Vijayalingam S, Chinnadurai G. Adenovirus L-E1A activates transcription through mediator complex-dependent recruitment of the super elongation complex. *J Virol*. 2013;87(6):3425–3434.
34. Konig R, et al. Human host factors required for influenza virus replication. *Nature*. 2010;463(7282):813–817.
35. Nguyen DG, Wolff KC, Yin H, Caldwell JS, Kuhlen KL. “UnPAKing” human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. *J Virol*. 2006;80(1):130–137.
36. Bakre A, et al. Identification of host kinase genes required for influenza virus replication and the regulatory role of microRNAs. *Plos One*. 2013;8(6):e66796.
37. Cheng F, et al. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. *PLoS Pathog*. 2009;5(3):e1000324.
38. Lee JH, Yedavalli VR, Jeang KT. Activation of HIV-1 expression and replication by cGMP dependent protein kinase type 1- β (PKG1 β). *Retrovirology*. 2007;4:91.
39. Coito C, Diamond DL, Neddermann P, Korth MJ, Katze MG. High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. *J Virol*. 2004;78(7):3502–3513.
40. Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. *J Gen Virol*. 2009;90(pt 8):1869–1879.
41. Jamaluddin M, Tian B, Boldogh I, Garofalo RP, Brasier AR. Respiratory syncytial virus infection induces a reactive oxygen species-MSK1-phospho-Ser-276 RelA pathway required for cytokine expression. *J Virol*. 2009;83(20):10605–10615.
42. Hsu MJ, Hung SL. Antiherpetic potential of 6-bromoindirubin-3'-acetoxime (BIO-acetoxime) in human oral epithelial cells. *Arch Virol*. 2013;158(6):1287–1296.
43. Guendel I, et al. Novel neuroprotective GSK-3 β inhibitor restricts Tat-mediated HIV-1 replication. *J Virol*. 2014;88(2):1189–1208.
44. Zhang J, Li G, Ye X. Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. *J Virol*. 2010;84(24):12619–12627.
45. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. *Mol Cell Biol*. 1999;19(7):4592–4599.
46. Wang S, Zhang J, Ye X. [Protein kinase inhibitor flavopiridol inhibits the replication of influenza virus in vitro]. *Wei Sheng Wu Xue Bao*. 2012;52(9):1137–1142.
47. Ali A, et al. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. *Chembiochem*. 2009;10(12):2072–2080.
48. Mancebo HS, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. *Genes Dev*. 1997;11(20):2633–2644.
49. Zhu Y, et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. *Genes Dev*. 1997;11(20):2622–2632.

RBFOX and SUP-12 sandwich a G base to cooperatively regulate tissue-specific splicing

Kanako Kuwasako^{1-3,14}, Mari Takahashi^{1,2,14}, Satoru Unzai⁴, Kengo Tsuda^{1,2}, Seiko Yoshikawa¹, Fahu He¹, Naohiro Kobayashi^{1,5}, Peter Güntert⁶⁻⁹, Mikako Shirouzu^{1,2}, Takuhiro Ito^{1,2}, Akiko Tanaka^{1,2}, Shigeyuki Yokoyama^{1,10}, Masatoshi Hagiwara^{11,12}, Hidehito Kuroyanagi^{11,13} & Yutaka Muto¹⁻³

Tissue-specific alternative pre-mRNA splicing is often cooperatively regulated by multiple splicing factors, but the structural basis of cooperative RNA recognition is poorly understood. In *Caenorhabditis elegans*, ligand binding specificity of fibroblast growth factor receptors (FGFRs) is determined by mutually exclusive alternative splicing of the sole FGFR gene, *egl-15*. Here we determined the solution structure of a ternary complex of the RNA-recognition motif (RRM) domains from the RBFOX protein ASD-1, SUP-12 and their target RNA from *egl-15*. The two RRM domains cooperatively interact with the RNA by sandwiching a G base to form the stable complex. Multichromatic fluorescence splicing reporters confirmed the requirement of the G and the juxtaposition of the respective *cis* elements for effective splicing regulation *in vivo*. Moreover, we identified a new target for the heterologous complex through an element search, confirming the functional significance of the intermolecular coordination.

Alternative splicing plays a substantial part in the production of appropriate protein isoforms for various developmental stages and tissue types¹, and a number of diseases have been reported to be associated with dysfunction of alternative splicing^{2,3}. A variety of splicing-regulatory factors prerequisitely bind to specific sites on precursor mRNAs (pre-mRNAs) to control exon inclusion or exclusion⁴⁻⁹. However, the binding sequences for many of the RNA-binding proteins lack tight consensus, and therefore cooperative recognition of the target pre-mRNAs by multiple splicing-regulatory factors is expected for accurate splicing regulation *in vivo*.

RNA-binding protein, fox-1 homolog (*C. elegans*) (RBFOX) family proteins are well-documented and evolutionarily conserved splicing regulators with important roles in tissue-specific alternative splicing in metazoans¹⁰. The RBFOX family proteins are characterized by their single and nearly invariant RRM domain, which specifically binds to a (U)GCAUG element with extraordinarily high affinity¹¹. The (U)GCAUG element is enriched in flanking introns of alternative exons regulated in neuron-specific or muscle-specific manners in mammals^{7,12-15}. Indeed, RBFOX1 and RBFOX2 are predominantly expressed in the brain, skeletal muscle and heart, although RBFOX2 is present in many cell types^{16,17}, and RBFOX3 is expressed exclusively in neurons¹⁸. Comparative genomic analysis of evolutionarily conserved intronic UGCAUG elements¹⁹ as well as genome-wide identification of binding sites for RBFOX2 in human embryonic

stem cells²⁰ has revealed many alternative-splicing events regulated by the RBFOX family and has elucidated a position-dependent trend of splicing regulation via the (U)GCAUG elements. Nevertheless, some of the alternative exons with the UGCAUG element(s) in the flanking introns are oppositely regulated in brain and muscle tissues or are unresponsive to expression or knockdown of the RBFOX proteins¹⁹, thus suggesting that other tissue-specific splicing regulators may be required for proper regulation of the brain- or muscle-specific splicing of the RBFOX-target exons.

In *C. elegans*, ligand binding specificity of FGFRs is determined by mutually exclusive selection of exon 5A or exon 5B of the *egl-15* gene encoding the sole homolog of the FGFRs²¹. The EGL-15(5A) isoform is required for directed migration of hermaphrodite sex myoblasts toward the center of the body, where its specific ligand, EGL-17, is expressed²¹. However, the EGL-15(5B) isoform and its specific ligand, LET-756, exert essential functions in embryonic and larval development²²⁻²⁵. We previously visualized the tissue-specific selection patterns of *egl-15* exon 5A and exon 5B in living worms with bichromatic fluorescence reporter minigenes²⁶. Through genetic and biochemical analyses, we demonstrated that the *C. elegans* RBFOX family proteins ASD-1 and FOX-1 cooperate with SUP-12, a member of the SUP-12-RBM24-RBM38 family proteins for muscle-specific production of EGL-15(5A) *in vivo*²⁷. Both ASD-1 and FOX-1 are expressed in a wide variety of tissues²⁷, like RBFOX2 in mammals,

¹RIKEN Systems and Structural Biology Center, Yokohama, Japan. ²RIKEN Center for Life Science Technologies, Yokohama, Japan. ³Faculty of Pharmacy and Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Japan. ⁴Graduate School of Nanobioscience, Yokohama City University, Yokohama, Japan. ⁵Institute for Protein Research, Osaka University, Suita, Japan. ⁶Tatsuo Miyazawa Memorial Program, RIKEN Genomic Sciences Center, Yokohama, Japan. ⁷Institute of Biophysical Chemistry, Center for Biomolecular Magnetic Resonance, Goethe University Frankfurt, Frankfurt am Main, Germany. ⁸Frankfurt Institute of Advanced Studies, Goethe University Frankfurt, Frankfurt am Main, Germany. ⁹Department of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, Japan. ¹⁰RIKEN Structural Biology Laboratory, Yokohama, Japan. ¹¹Graduate School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, Japan. ¹²Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ¹³Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan. ¹⁴These authors contributed equally to this work. Correspondence should be addressed to M.H. (hagiwara.masatoshi.8c@kyoto-u.ac.jp), H.K. (kuroyana.end@tmd.ac.jp) or Y.M. (ymuto@musashino-u.ac.jp).

Received 26 May; accepted 14 July; published online 17 August 2014; doi:10.1038/nsmb.2870

whereas SUP-12 is muscle specific²⁸, thus indicating that functional coordination between these factors is crucial for the muscle-specific selection of *egl-15* exon 5A. Furthermore, *asd-1*; *fox-1* and *asd-1*; *sup-12* double-mutant worms are defective in the directed migration of the sex myoblasts and in egg laying (*Egl-d*)^{26,27}, the same phenotypes as in the *egl-15(5A)* and *egl-17* mutants, thus emphasizing that *egl-15* exon 5 is the essential physiological target for the RBFOX family in nematodes.

We previously identified a UGCAUGGUGUGC stretch located just upstream of the splice-acceptor site for exon 5B as a *cis* element allowing the RBFOX family and SUP-12 to cooperatively repress exon 5B^{26,27} (Fig. 1a). The RBFOX family proteins specifically recognize the first 6-nt UGCAUG segment, whereas SUP-12, which also has a single RRM domain, is expected to bind to the latter GUGUGC segment²⁷. However, the precise RNA sequence specificity of SUP-12 is not yet clear, and it remains obscure why two RRM proteins are necessary for the effective regulation of the *egl-15* pre-mRNA.

We set out to elucidate the structural basis for the cooperative RNA recognition by the RBFOX family proteins and SUP-12. We thus determined solution structures of a binary complex consisting of SUP-12 RRM and 5'-GUGUGC-3' and a ternary complex consisting of ASD-1 RRM, SUP-12 RRM and 5'-UGCAUGGUGUGC-3'. We found that muscle-specific regulation of *egl-15* alternative splicing requires appropriate positioning of the two RRM domains that sandwich the G base at the seventh position in the RNA sequence. We confirmed the rigidity and the flexibility in their cooperativity predicted from the structural analysis with our *egl-15* splicing-reporter system *in vivo*.

RESULTS

Cooperative RNA binding by RRM domains of ASD-1 and SUP-12

We previously reported cooperative binding of full-length ASD-1 and full-length SUP-12 to the *egl-15* pre-mRNA *in vitro*²⁷. Here, we first created ASD-1 and SUP-12 fragments and then determined which of them were capable of RNA binding. For ASD-1, we used a fragment spanning residues 97–190 (hereafter termed ASD-1 RRM), according to a previous report on the identical RRM domains of mammalian RBFOX1 (ref. 11), which share high sequence identity with that of ASD-1 (Supplementary Fig. 1). For SUP-12, NMR chemical-shift-perturbation analyses revealed that a fragment spanning residues 20–121 (SUP-12 RRM) was sufficient for binding to the RNA oligonucleotide 5'-GUGUGC-3' (RNA₆) (Supplementary Fig. 2a,b). Next, we tested whether the RRM domains are sufficient for cooperative RNA binding by performing an electrophoretic mobility shift assay (EMSA) experiment with 10 nM of the RNA oligonucleotide 5'-UGCAUGGUGUGC-3' (RNA₁₂) and ASD-1 RRM and/or SUP-12 RRM. In the case of ASD-1 RRM, a 1:1 protein–RNA binary complex (ASD-1–RNA₁₂ complex) was mainly formed (Fig. 1b). When we added only SUP-12 RRM to RNA₁₂, we observed a smeared signal, and the mobility of the RNA gradually shifted according to the increase in the amount of SUP-12 RRM (Fig. 1c), thus implying that SUP-12 RRM alone lacked strict RNA sequence specificity and that multiple SUP-12 RRM molecules can bind to multiple sites in RNA₁₂. Then we added SUP-12 RRM to RNA₁₂ in the presence of 25.6 μM ASD-1 RRM (Fig. 1d). In this case, SUP-12 RRM supershifted a band corresponding to the ASD-1–RNA₁₂ complex to form another clear band (Fig. 1d), indicating the formation of a ternary complex. The ternary




Figure 1 The RBFOX family and SUP-12 cooperatively regulate alternative splicing of *egl-15* pre-mRNA. **(a)** Schematic representation of mutually exclusive alternative splicing of exon 5A and exon 5B of the *egl-15* pre-mRNA (details in main text). **(b–d)** EMSA using a radiolabeled RNA₁₂ probe without (–) or with the indicated concentrations of ASD-1 RRM (**b**), SUP-12 RRM (**c**) and both (**d**) recombinant proteins. Representative images from two independent experiments are shown. **(e,f)** ITC measurements of SUP-12 RRM binding to RNA₁₂ (**e**) and to ASD-1–RNA₁₂ binary complexes (**f**). The results shown are one of two technical replicates. Raw data as functions of time are shown at top, and plots of the total heat released as functions of the molar ratio of the RNA are shown at bottom. The experimental data were fitted to a theoretical titration curve with software supplied by MicroCal. The continuous lines represent the nonlinear least-squares best fit to the experimental data, with a one-site model.




Figure 2 Solution structures of SUP-12-RNA₆ and ASD-1-SUP-12-RNA₁₂ complexes. **(a,b)** Ribbon representations of the SUP-12-RNA₆ complex **(a)** and the ASD-1-SUP-12-RNA₁₂ complex **(b)**. SUP-12 RRM and ASD-1 RRM are colored white and gray, respectively. The G, A, U and C nucleotides are shown in light blue, pink, light green and yellow, respectively. The side chains in the RRM domains involved in the G7-base recognition are represented as follows: black, carbon; red, oxygen; blue, nitrogen. **(c)** Schematic diagrams of the SUP-12-RNA₆ complex (left) and the ASD-1-SUP-12-RNA₁₂ complex (right). **(d,e)** Electrostatic-potential surfaces of the RRM domains in the SUP-12-RNA₆ complex **(d)** and the ASD-1-SUP-12-RNA₁₂ complex **(e)**. Red and blue indicate negative and positive charges, respectively. The RNA molecule is colored yellow.

complex was formed at a lower concentration of SUP-12 RRM than was required for the formation of the SUP-12-RNA₁₂ binary complex (Fig. 1c). These results suggested that ASD-1 RRM anchored SUP-12 RRM to the appropriate position on the target RNA to form a stable ternary complex at a molar ratio of 1:1:1.

In order to assess the cooperativity between ASD-1 RRM and SUP-12 RRM, we also performed isothermal titration calorimetry (ITC) experiments by using SUP-12 RRM, the RNA oligonucleotides and a preformed ASD-1-RNA₁₂ binary complex (Fig. 1e,f). SUP-12 RRM exhibited an apparent K_d value of 565 nM for binding RNA₁₂ (Fig. 1e). Consistently with the EMSA experiments, SUP-12 RRM bound more effectively to the preformed ASD-1-RNA₁₂ binary complex, with a K_d of 42.4 nM (Fig. 1f). The ITC experiments also revealed that SUP-12 RRM by itself could bind to some extent to other RNA stretches with GU and/or UG element(s) flanking the canonical binding site (Supplementary Fig. 3a–e), whereas ASD-1 RRM specifically bound to the UGCAUGG stretch (Supplementary Fig. 3a,f–h). The wobble RNA recognition of SUP-12 RRM may explain the EMSA results in which SUP-12 RRM alone shifted the mobility of RNA₁₂ in a non-uniform manner and hypershifted the mobility more effectively than ASD-1 RRM alone (Fig. 1b–d). Thus, the EMSA and ITC experiments indicated that ASD-1 RRM guides SUP-12 RRM to the proper site to effectively form the stable ASD-1-SUP-12-RNA₁₂ ternary complex.

Structural basis for cooperative RNA recognition

In order to elucidate the structural basis for the cooperation between ASD-1 and SUP-12, we solved a solution structure of a binary complex composed of SUP-12 RRM and 5'-GUGUGC-3' (SUP-12-RNA₆ complex) (Fig. 2a,c,d, Supplementary Fig. 2c,d, Table 1 and Supplementary Tables 1 and 2) and that of the ternary complex composed of ASD-1 RRM, SUP-12 RRM and 5'-UGCAUGGUGUGC-3' (ASD-1-SUP-12-RNA₁₂ complex) (Fig. 2b,c,e, Supplementary Fig. 4, Table 1 and Supplementary Tables 3 and 4).

In the ternary complex, ASD-1 RRM and SUP-12 RRM were arranged side by side in fixed positions and formed positively charged surfaces for RNA recognition (Fig. 2b,c,e and Supplementary Fig. 4c,d). All of the nucleotide residues (U1–C12) interacted with either or both of the RRM domains: U1–G6 were located on ASD-1 RRM, G7 was sandwiched between the two RRM domains, and U8–C12 were on SUP-12 RRM (Fig. 2b and Supplementary Fig. 4c–e).

The RNA-recognition mode of ASD-1 RRM in the ternary complex was essentially the same as that of the single RRM domain of mammalian RBFOX1 in a binary complex with 5'-UGCAUGU-3' except for the base at the seventh position; the U base is not fixed on the body of the RRM domain of RBFOX1 (ref. 11). The mode of recognition of G9–C12 by SUP-12 RRM was common between the SUP-12-RNA₆ and the ASD-1-SUP-12-RNA₁₂ complexes (Fig. 2a–c). The G9 base

Table 1 Data collection and refinement statistics

	SUP-12-RNA ₆	ASD-1-SUP-12-RNA ₁₂
NMR distance and dihedral constraints		
Distance restraints		
Total NOE	1,640	1,839
Intra-residue	428	602
Inter-residue		
Sequential ($ i - j = 1$)	400	519
Non-sequential ($ i - j > 1$)	812	718
Hydrogen bonds ^a	40	112
Protein–nucleic acid intermolecular	67	122
Total dihedral angle restraints		
Protein		
ϕ	2	5
ψ	2	5
Nucleic acid		
Base pair	0	4
Sugar pucker	6	12
Backbone	6	12
Total RDCs (HN–N) ^b	–	69
Average correlation	–	0.963 ± 0.007
Average <i>Q</i>	–	0.272 ± 0.021
Structure statistics		
Violations (mean and s.d.)		
Distance constraints (Å) > 0.1	0.145 ± 0.028	0.134 ± 0.036
Dihedral angle constraints (°)	0	0
Max. dihedral angle violation (°)	0	0
Max. distance constraint violation (Å)	0.186 ± 0.024	0.188 ± 0.047
Deviations from idealized geometry		
Bond lengths (Å)	0.014	0.014
Bond angles (°)	1.8	1.9
Average pairwise r.m.s. deviation (Å)		
Protein ^c		
Heavy	1.19 ± 0.14	2.52 ± 0.69
Backbone	0.45 ± 0.09	2.09 ± 0.69
RNA ^d		
All RNA heavy	1.27 ± 0.47	2.13 ± 0.68
Complex ^e		
Protein and nucleic acid heavy	1.24 ± 0.15	2.59 ± 1.00

^aUsed only in CYANA calculation. ^bUsed only in AMBER calculation. ^cFor the calculated residues, the proteins were Ile37–Ala114 of SUP-12 RRM and Leu102–Ala174 of ASD-1 RRM. ^dFor the calculated residues, the RNAs were G7–C12 in the SUP-12-RNA₆ complex and U1–C12 in the ASD-1-SUP-12-RNA₁₂. ^eFor the calculated residues, the proteins and RNAs were Ile37–Ala114 and G7–C12 in the SUP-12-RNA₆ complex and Leu102–Ala174 and U1–C12 of ASD-1-SUP-12-RNA₁₂.

was located in a pocket composed of Phe38, Tyr78 and Asn106 of SUP-12 (Fig. 3a). The O6 atom of G9 was recognized by the H^δ proton of Asn106 in the pocket (Fig. 3a). The U10 base was sandwiched between the conserved Phe38 residue of the RNP2 motif and a C-terminal extension of the RRM domain spanning residues Leu112 to Lys115 (Fig. 3b). Its functional moieties, the O4 atom and the imino proton, were recognized by hydrogen-bonding with the H^δ amide proton of Asn108 and the main chain carbonyl oxygen atom of Ala110, respectively (Fig. 3b). The G11 base was stacked with the side chain of Phe80 on the RNP1 motif and that of Lys115 (Fig. 3c). Two hydrogen-bonding interactions were formed between the O6 atom of G11 and the amide proton of Lys115 and between the OP2 atom of G11 and the H^{ε3} atom of Lys115 (Fig. 3c). The C12 base stuck into the space composed of Ile67 and Arg70; the O2 atom of C12 could be hydrogen-bonded to a proton of the guanidyl group of Arg70 (Fig. 3d).

ASD-1 RRM altered the mode of RNA recognition by SUP-12 RRM

In the ASD-1-SUP-12-RNA₁₂ complex, the side chain of Arg177 of ASD-1 RRM intruded into the space between the G6 nucleotide on ASD-1 RRM and the U8 nucleotide on SUP-12 RRM to interact with the phosphate backbones of the G6, G7 and G9 nucleotides (Figs. 2b and 3e). Accordingly, the recognition modes for the G7 and U8 bases by SUP-12 RRM were quite different between the SUP-12-RNA₆ and the ASD-1-SUP-12-RNA₁₂ complexes.

The G7 base was buried in a groove formed by the β1–α1 and the α2–β4 loops and was sandwiched between Tyr44 and Arg103 in the SUP-12-RNA₆ complex (Fig. 2a,c,d). The imino proton of the G7 base formed a hydrogen bond with the main chain carboxyl oxygen of Leu42 and exhibited several nuclear Overhauser effects (NOEs) with SUP-12 RRM (Supplementary Fig. 5a). Thus, the G7 base was fairly strictly recognized in the SUP-12-RNA₆ binary complex. Correspondingly, ITC experiments revealed that SUP-12 RRM exhibited the lower affinity for the G7-substituted RNA oligonucleotides AUGUGC, CUGUGU and UUGUGC (with substituted oligonucleotides underlined here and subsequently) than for RNA₆ (Supplementary Fig. 5c–f).

In the ASD-1-SUP-12-RNA₁₂ complex, the G7 base was sandwiched between ASD-1 Ile132 and SUP-12 Tyr44 and was surrounded by a wall formed by ASD-1 Glu130 and SUP-12 Arg103 to fix the spatial relationship between ASD-1 RRM and SUP-12 RRM (Fig. 3e). The χ₂ angle of SUP-12 Tyr44 was altered to maintain the stacking interaction with the G7 base as described above (Figs. 2b and 3e). Correspondingly, the imino-proton resonance from the G7 base was missing in the ASD-1-SUP-12-RNA₁₂ complex (Supplementary Fig. 5b).

The U8 base was barely recognized in the SUP-12-RNA₆ complex (Fig. 3f). In the ASD-1-SUP-12-RNA₁₂ complex, the alternation of the χ₂ angle of SUP-12 Tyr44 induced re-formation of the pocket that accommodated G9 (Figs. 2b and 3f), and the U8 base intruded into the pocket to stack with the G9 base. The sugar moiety of U8 was also stacked with ASD-1 Arg177, and the O4 atom of U8 was recognized by the H^ε and H^{η21} amide protons of SUP-12 Arg103 (Fig. 3f). Consistently with the relocation of U8 to the pocket, five intermolecular NOEs were present between the U8 base and the two RRM domains in the ASD-1-SUP-12-RNA₁₂ complex, whereas only one NOE was present between the U8 base and SUP-12 RRM in the SUP-12-RNA₆ complex (Supplementary Tables 1 and 3). The solution structure thus revealed that the stacking of the U8 base with the G9 base and ASD-1 Arg177 was a dominant interaction for U8 recognition in the ASD-1-SUP-12-RNA₁₂ complex. However, the space beside the U8 base was large enough for the other bases (Supplementary Fig. 6a).

The role of the G7 base in ternary-complex formation

The G7-recognition mode in the ASD-1-SUP-12-RNA₁₂ ternary complex was distinct from that in the SUP-12-RNA₆ binary complex, as described above. Analyses of the solution structures described above predicted that G7 was the key nucleotide for the cooperation between ASD-1 RRM and SUP-12 RRM through the sandwich-like hydrophobic interactions, because a G base is preferable for such hydrophobic interactions with hydrophobic amino acid residues. To test whether an A base could substitute for the G at this position, we obtained an NMR spectrum of a mutant ternary complex containing a G7A-mutant oligonucleotide 5'-UGCAUGAUGUGC-3' (RNA₁₂(G7A)). The spectrum indicated that both of the RRM domains bound to RNA₁₂(G7A) and that the A base resided at the position corresponding to the G7 base (Fig. 4a). In contrast to the wild-type ASD-1-SUP-12-RNA₁₂ complex (Fig. 4b), however, the resonances of the following UG dinucleotide (U8 and G9) were missing in the G7A-mutant complex (Fig. 4a),







Figure 3 Close-up views of the ASD-1-SUP-12-RNA₁₂ and SUP-12-RNA₆ complexes. (a–d) The recognition contacts for G9 (a), U10 (b), G11 (c) and C12 (d) in the ASD-1-SUP-12-RNA₁₂ complex. The side chains of the RRM domains involved in RNA recognition are represented as follows: green, carbons in SUP-12 RRM; orange, carbons in ASD-1 RRM; red, oxygens; blue, nitrogens. The RNA molecule is represented by a ball-and-stick model with atoms colored as follows: dark gray, carbon; red, oxygen; blue, nitrogen; yellow, phosphorus. The base-specific hydrogen bonds, calculated by AMBER, are represented by dashed cyan lines (also **Supplementary Tables 3 and 4**). (e) Stereo view of cooperative G7 recognition by ASD-1 RRM and SUP-12 RRM in the ASD-1-SUP-12-RNA₁₂ complex. (f) Comparison of U8- and G9-recognition contacts between the SUP-12-RNA₆ complex (top) and the ASD-1-SUP-12-RNA₁₂ complex (bottom) in stereo views.

thus indicating that the recognition of these two nucleotides by SUP-12 RRM was weakened, and the cooperativity between the two RRM domains was probably lost.

Then we analyzed NMR dynamics parameters for the wild-type and the mutant ternary complexes by measuring backbone-nitrogen relaxation times T_1 and T_2 and proton-nitrogen heteronuclear NOEs. The correlation time ($\tau_c = 10.2$ ns) and relatively large deviations of the T_1 and T_1/T_2 values for each of the RRM domains indicated that the ASD-1-SUP-12-RNA₁₂ complex was shaped like a prolate spheroid and behaved in one united body (**Supplementary Fig. 6b**). In the G7A-mutant complex, in contrast, the deviations were in a small range, and the correlation time did not correspond to the appropriate molecular weight for the rigid ternary complex

Figure 4 Recognition of the U8 and G9 bases is weakened in the G7A-mutant complex. (a, b) The H2, H6 and H8 regions of 2D ^1H - ^1H NOESY spectra of the G7A mutant (a) and the wild-type (b) ASD-1-SUP-12-RNA₁₂ complexes at 298 K. The assignments of the H2, H6 and H8 atoms in the RNA molecules are indicated with blue and green lines. The assignment of the H8 atom of A7 is indicated with a dashed red line in a. Asterisks in a denote unsuccessful assignment of the H6 atom of U8 and the H8 atom of G9 for the mutant complex, indicating weakened recognition of the U8 and G9 bases by SUP-12 RRM.



(**Supplementary Fig. 6c**). These data suggested that the low binding activity of SUP-12 RRM to the mutant RNA and/or the poor fitting of A7–G9 on SUP-12 RRM caused the lower rigidity of the G7A-mutant complex.

We also performed ITC analysis with a preformed ASD-1-RNA₁₂(G7A) binary complex and found that binding of SUP-12 RRM to the ASD-1-RNA₁₂(G7A) complex (**Fig. 5a**) was reduced as




Figure 5 ASD-1 RRM guides SUP-12 RRM to form the stable ASD-1-SUP-12-RNA₁₂ ternary complex. **(a,b)** ITC measurements of SUP-12 RRM binding to two types of mutant binary complexes: ASD-1-RNA₁₂(G7A) **(a)** and ASD-1(E130R)-RNA₁₂ **(b)**. **(c,d)** ITC measurements of the binding of SUP-12(R103E) RRM to the preformed ASD-1-RNA₁₂ binary complex **(c)** and to RNA₆ **(d)**. The data are analyzed and represented as in **Figure 1f,g**. For each of the ITC experiments, data were obtained from single technical trial, owing to the difficulty of the preparation of the purified binary complex. **(e,f)** EMSA experiments using a radiolabeled RNA₁₂ probe with a dilution series of ASD-1(E130R) RRM alone **(e)** and with a dilution series of SUP-12 RRM in the presence of 25.6 μM ASD-1(E130R) RRM **(f)**. For each of the experiments, a representative image from two independent experiments is shown.

compared to binding to the wild-type ASD-1-RNA₁₂ binary complex (**Fig. 1f**). All these data supported the idea that the G7 base was crucial for ASD-1 RRM and SUP-12 RRM to cooperatively recognize the *egl-15* pre-mRNA and form the stable and rigid ternary complex.

Although we did not observe a direct NOE between ASD-1 RRM and SUP-12 RRM, NOEs from the G7 and U8 nucleotides to Ile132 and Arg177 of ASD-1 and to Tyr44 and Arg103 of SUP-12 fixed the spatial relationship between ASD-1 RRM and SUP-12 RRM (**Supplementary Table 3**). We confirmed the orientation of the two RRM domains by residual dipolar coupling (RDC) experiments (**Supplementary Fig. 4b**). Correspondingly, the side chains of ASD-1 Ile132 and SUP-12 Tyr44 and the G7 base were well converged (**Supplementary Fig. 4e**).

From the structural information, we expected direct electrostatic interactions between Asp128 and Glu130 of ASD-1 and Arg103 of SUP-12 in the ASD-1-SUP-12-RNA₁₂ complex (**Figs. 2b** and **3e** and **Supplementary Fig. 4e**). However, we did not confirm the interactions with the NMR data because carboxyl groups in the side chains of Asp128 and Glu130 had no protons for NOE measurements.

In order to elucidate the requirement for the interaction between ASD-1 Glu130 and SUP-12 Arg103, we prepared a mutant protein ASD-1(E130R) RRM and performed EMSA and ITC experiments. The EMSA experiments demonstrated that ASD-1(E130R) RRM by itself exhibited the same RNA binding activity to RNA₁₂ (**Fig. 5e**) as wild-type ASD-1 RRM (**Fig. 1b**). However, the formation of the ASD-1(E130R)-SUP-12-RNA₁₂ ternary complex was diminished (**Fig. 5f**) compared to formation of the wild-type ternary complex (**Fig. 1d**). The ITC experiment revealed that the K_d value of SUP-12

RRM for binding to the preformed ASD-1-RNA₁₂ complex was weakened from 42.4 nM for the wild-type complex (**Fig. 1f**) to 1.46 μM for the E130R-mutant complex (**Fig. 5b**). These results indicated that ASD-1 Glu130 was essential for the intermolecular interaction between the ASD-1-RNA₁₂ complex and SUP-12 RRM and not for the RNA binding activity of ASD-1 RRM.

SUP-12 Arg103 was also involved in RNA recognition in distinct ways in the binary and the ternary complexes (**Figs. 2** and **3e,f**). ITC experiments with a mutant protein SUP-12(R103E) RRM revealed that the mutation in SUP-12 Arg103 more profoundly affected the binding of SUP-12 RRM to the ASD-1-RNA₁₂ binary complex than to RNA₆ (**Fig. 5c,d**), confirming that SUP-12 Arg103 is one of the key residues for the cooperative formation of the ASD-1-SUP-12-RNA₁₂ complex.

Conclusively, the present structural studies delineated three characteristic cooperative effects that stabilize the ASD-1-SUP-12-RNA₁₂ ternary complex: the intrusion of Arg177 of ASD-1 RRM to interact with the G6-U8 stretch, the sandwich-like recognition of the G7 base and the electrostatic interaction between ASD-1 and SUP-12. In cooperation with ASD-1, which specifically recognizes the UGCAUG stretch, SUP-12 accurately recognized the GUGUGC stretch with higher affinity.

The G7 base was crucial for splicing regulation *in vivo*

In order to confirm the structural model in the actual regulation of alternative splicing *in vivo*, we performed mutation analyses of fluorescent *egl-15* splicing reporter (**Fig. 6**). RFP was predominantly expressed from the wild-type minigene (**Fig. 6a**), thus reflecting exon 5A selection in body-wall muscles^{26,27}, whereas GFP was

Figure 6 The sandwiched base G7 and not U8 is crucial for regulation of muscle-specific alternative splicing *in vivo*. (a–l) Microphotographs of *egl-15* reporter worms carrying wild-type (a) and mutant (b–l) *egl-15BGAR* minigenes, acquired with a dual-band-pass filter. (b,c) Substitution mutations of the RBFOX site (b) and the SUP-12 site (c). (d–f) Substitution mutations of the G7 base: G7A (d), G7C (e) and G7U (f). (g–i) Substitution mutations of the U8 base: U8A (g), U8C (h) and U8G (i). (j–l) Insertion mutations with three extra bases between the elements: AAA (j), ACA (k) and ACC (l). The sequences of the *cis* elements are indicated with the altered residues underlined. Scale bar, 200 μ m. The images were processed so that the images in the red channel appear in magenta. These microphotographs are representative of three or more transgenic lines (a,c,d,f,g,j–l) and of one or two transgenic lines (b,e,h,i).

predominantly expressed from mutant minigenes lacking the consensus for either RBFOX or SUP-12 (Fig. 6b,c), thus indicating exon 5B selection. When the G7 base was replaced with the other bases (i.e., A, C or T) in the minigenes, the color of the worms also changed to green (Fig. 6d–f), a result confirming that the G7 base was crucial for the muscle-specific splicing regulation of the *egl-15* gene *in vivo*.

However, when the T8 base was replaced with the other bases (i.e., A, C or G), the body-wall muscles remained red or orange (Fig. 6g–i), as we had speculated would happen, on the basis of the solution structure. Indeed, the T8 base of the tandem elements is not fully conserved in the *egl-15* gene of related nematode species but is replaced with C in *Caenorhabditis briggsae* (Supplementary Fig. 7a). These data confirmed that the U8 base was not crucially involved in splicing regulation.

To investigate the importance of the distance between the respective *cis* elements, we inserted three nucleotides (AAA, ACA or ACC) between G6 and G7 in the minigene. These insertions drastically changed the color of the splicing-reporter worms (Fig. 6j–l), indicating that proper positioning of the *cis* elements for the two RRM proteins is crucial for the splicing regulation of *egl-15* exon 5 *in vivo*.

Conservation of the cooperative splicing regulation

We speculated that a UGCAUG stretch immediately followed by a GYGUG stretch in introns flanking an alternative exon may predict cooperative regulation of the exon by the RBFOX family and SUP-12 in *C. elegans*. To test this idea, we searched the *C. elegans* genome for the UGCAUGGYGUG sequence. We found that 14 out of 47 UGCAUGGYGUG sites in the genome reside in the sense strand of protein-coding genes including *egl-15*. Among them, the *cle-1* gene, encoding the sole homolog of vertebrate type XV and type XVIII





Figure 7 A highly conserved UGCAUGGUGUG stretch in *cle-1* intron 16 successfully predicts the activation of exon 16 by the RBFOX family and SUP-12. Reverse-transcription PCR analyses of endogenous *cle-1* exon 16 (left) and *egl-15* exons 5A and 5B (right) in the wild-type strain (N2), the *asd-1; fox-1* double mutant and the *sup-12* mutant. Changes in percentage spliced in ($\Delta\Psi$) in molar concentration as compared to N2 are indicated. The results shown are from one of two technical replicates.



collagen, has a highly conserved UGCAUGGUGUG stretch in the downstream intron of its cassette exon (Supplementary Fig. 7b). Consistently with the observations that the RBFOX family and the UGCAUG stretch(es) in the downstream introns tend to promote inclusion of cassette exons in mammals^{19,20} and nematodes (H.K., unpublished data), we confirmed that the inclusion level of *cle-1* exon 16 was decreased in the *asd-1; fox-1* double mutant and was highly dependent on SUP-12 (Fig. 7), thus confirming that *cle-1* exon 16 was a common target for the RBFOX family and SUP-12 *in vivo*. To our knowledge, this is the first successful prediction and validation of a new target pre-mRNA for SUP-12 based on the combination of the splicing-regulatory elements, and our results emphasize the importance of cooperative splicing regulation by the RBFOX family and SUP-12.

DISCUSSION

In this study, we elucidated the cooperative RNA-recognition mode of ASD-1 and SUP-12. When ASD-1 RRM binds to the UGCAUG stretch, SUP-12 binds to the juxtaposed GUGUG stretch with higher affinity and specificity, to form a tight ternary complex with the G7 base sandwiched between them.

So far, two types of cooperative and specific RNA recognition by multiple RRM domains have been elucidated. One is the intermolecular protein-protein interaction between Hrp1 and Rna15 on the scaffold protein Rna14 for tight RNA binding in yeast. In this case, the RRM domains of Hrp1 and Rna15 separately recognize their own target sequences without any cooperation²⁹. Another is the intramolecular cooperation between two RRM domains in a single molecule, such as *Drosophila* Sxl³⁰. Intermolecular cooperation between RRM domains for specific base recognition, as we observed between ASD-1 and SUP-12, had not been reported previously, to our knowledge. We identified the combinations of the amino acid residues in ASD-1 and SUP-12 involved in the cooperative recognition (Fig. 3e). We could not find the combinations of residues among all of the 705 human RRM domains in the Pfam database (release 26.0). Thus, we consider the sandwich-like RNA recognition by the RBFOX family and SUP-12 to be unique among the RRM proteins.

The muscle-specific RNA-binding protein SUP-12 confers muscle specificity in the RBFOX-mediated splicing regulation of *egl-15* exon 5 (ref. 27). Similarly, a neuron-specific CELF family RNA-binding protein, UNC-75, confers neuron specificity in RBFOX-mediated splicing regulation of *unc-32* exon 7 (refs. 31,32). In mammals, some cassette exons with UGCAUG stretches in their flanking introns are oppositely regulated in brain and muscle tissues¹⁹. These facts suggest a general model in which specific binding of the RBFOX family to the UGCAUG stretch(es) is necessary yet insufficient for proper splicing regulation and that other tissue-specific factors are required for combinatorial splicing regulation. One possible reason why the high-affinity binding of the RBFOX family is insufficient might be that occupancy of most of the UGCAUG stretches by the RBFOX family proteins is low, owing to their low concentration *in vivo*, and this is overcome by cooperative recognition, as shown in the present study. This view is supported by splicing autoregulation of the RBFOX family to strictly maintain RBFOX expression level in mammals³³ and *C. elegans* (H.K., unpublished data).

We also demonstrated that the cooperation relies on the appropriate distance of the *cis* elements for the RBFOX family and SUP-12. In the case of muscle-specific alternative processing of *unc-60* pre-mRNA, the target sequences for SUP-12 and ASD-2, a signal transduction and activation of RNA (STAR) family protein, are separated by three or more nucleotides^{34–36}, thus implying that the spatial relationship between the *cis* elements directing the cooperative recognition can vary according to the combination of splicing-regulatory factors. Future structural studies on the combinatorial recognition of target sequences by multiple RNA-binding proteins together with the confirmation experiments with multichromatic fluorescence splicing reporters will contribute to deciphering the detailed splicing codes *in vivo*.

METHODS

Methods and any associated references are available in the online version of the paper.

Accession codes. Chemical shifts of the SUP-12–RNA₆ complex and those of the ASD-1–SUP-12–RNA₁₂ complex have been deposited in the Biological Magnetic Resonance Data Bank under accession numbers 11517 and 11518, respectively. Atomic coordinates for the ensembles of 20 energy-refined NMR conformers, representing the solution structures of the SUP-12–RNA₆ and ASD-1–SUP-12–RNA₁₂ complexes, have been deposited in the Protein Data Bank under accession codes 2RU3 and 2MGZ, respectively.

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We thank H. Kurokawa for technical assistance and T. Imada, K. Ake and T. Nakayama for help with manuscript preparation. This work was supported by the RIKEN Structural Genomics/Proteomics Initiative (RSGI), the National Project on Protein Structural and Functional Analyses (to Sh.Y.) of the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Grants-in-Aid for Scientific Research on Innovative Areas “RNA Regulation” (no. 20112004 to H.K.; nos. 21112522 and 23112723 to Y.M.) and “Transcription Cycle” (no. 25118506 to H.K.) from MEXT, Grants-in-Aid for Scientific Research (B) (no. 23370080 to Y.M.; no. 26291003 to H.K.) from the Japan Society for the Promotion of Science (JSPS) and Precursory Research for Embryonic Science and Technology (PRESTO) from Japan Science and Technology Agency (JST) to H.K.

AUTHOR CONTRIBUTIONS

K.K. and M.T. performed the structure determinations of the SUP-12–RNA₆ complex and the ASD-1–SUP-12–RNA₁₂ complex by NMR. S.U. performed the

analytical ultracentrifugation experiments. Se.Y., M.S., T.I. and A.T. assisted with sample preparation. K.T., F.H., N.K., P.G. and Sh.Y. assisted with the structural determination. H.K. performed the *in vivo* splicing assays. The project was directed by M.H. and Y.M. All authors contributed to the preparation of the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Pan, Q., Shai, O., Lee, L.J., Frey, B.J. & Blencowe, B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nat. Genet.* **40**, 1413–1415 (2008).
- Cáceres, J.F. & Kornblihtt, A.R. Alternative splicing: multiple control mechanisms and involvement in human disease. *Trends Genet.* **18**, 186–193 (2002).
- Faustino, N.A. & Cooper, T.A. Pre-mRNA splicing and human disease. *Genes Dev.* **17**, 419–437 (2003).
- Busch, A. & Hertel, K.J. Evolution of SR protein and hnRNP splicing regulatory factors. *Wiley Interdiscip. Rev. RNA* **3**, 1–12 (2012).
- Chen, Y.I. *et al.* Proteomic analysis of *in vivo*-assembled pre-mRNA splicing complexes expands the catalog of participating factors. *Nucleic Acids Res.* **35**, 3928–3944 (2007).
- Ruskin, B., Zamore, P.D. & Green, M.R. A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly. *Cell* **52**, 207–219 (1988).
- Wang, E.T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476 (2008).
- Wu, S., Romfo, C.M., Nilsen, T.W. & Green, M.R. Functional recognition of the 3' splice site AG by the splicing factor U2AF35. *Nature* **402**, 832–835 (1999).
- Zhuang, Y. & Weiner, A.M. A compensatory base change in U1 snRNA suppresses a 5' splice site mutation. *Cell* **46**, 827–835 (1986).
- Kuroyanagi, H. Fox-1 family of RNA-binding proteins. *Cell. Mol. Life Sci.* **66**, 3895–3907 (2009).
- Auweter, S.D. *et al.* Molecular basis of RNA recognition by the human alternative splicing factor Fox-1. *EMBO J.* **25**, 163–173 (2006).
- Castle, J.C. *et al.* Expression of 24,426 human alternative splicing events and predicted *cis* regulation in 48 tissues and cell lines. *Nat. Genet.* **40**, 1416–1425 (2008).
- Das, D. *et al.* A correlation with exon expression approach to identify *cis*-regulatory elements for tissue-specific alternative splicing. *Nucleic Acids Res.* **35**, 4845–4857 (2007).
- Minovitsky, S., Gee, S.L., Schokrpur, S., Dubchak, I. & Conboy, J.G. The splicing regulatory element, UGCAUG, is phylogenetically and spatially conserved in introns that flank tissue-specific alternative exons. *Nucleic Acids Res.* **33**, 714–724 (2005).
- Sugnet, C.W. *et al.* Unusual intron conservation near tissue-regulated exons found by splicing microarrays. *PLoS Comput. Biol.* **2**, e4 (2006).
- Takeuchi, A., Hosokawa, M., Nojima, T. & Hagiwara, M. Splicing reporter mice revealed the evolutionally conserved switching mechanism of tissue-specific alternative exon selection. *PLoS ONE* **5**, e10946 (2010).
- Underwood, J.G., Boutz, P.L., Dougherty, J.D., Stoilov, P. & Black, D.L. Homologues of the *Caenorhabditis elegans* Fox-1 protein are neuronal splicing regulators in mammals. *Mol. Cell. Biol.* **25**, 10005–10016 (2005).
- Kim, K.K., Adelstein, R.S. & Kawamoto, S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. *J. Biol. Chem.* **284**, 31052–31061 (2009).
- Zhang, C. *et al.* Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. *Genes Dev.* **22**, 2550–2563 (2008).
- Yeo, G.W. *et al.* An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. *Nat. Struct. Mol. Biol.* **16**, 130–137 (2009).
- Goodman, S.J., Branda, C.S., Robinson, M.K., Burdine, R.D. & Stern, M.J. Alternative splicing affecting a novel domain in the *C. elegans* EGL-15 FGF receptor confers functional specificity. *Development* **130**, 3757–3766 (2003).
- Birnbaum, D., Popovici, C. & Roubin, R. A pair as a minimum: the two fibroblast growth factors of the nematode *Caenorhabditis elegans*. *Dev. Dyn.* **232**, 247–255 (2005).
- Burdine, R.D., Branda, C.S. & Stern, M.J. EGL-17(FGF) expression coordinates the attraction of the migrating sex myoblasts with vulval induction in *C. elegans*. *Development* **125**, 1083–1093 (1998).
- Burdine, R.D., Chen, E.B., Kwok, S.F. & Stern, M.J. egl-17 encodes an invertebrate fibroblast growth factor family member required specifically for sex myoblast migration in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. USA* **94**, 2433–2437 (1997).
- DeVore, D.L., Horvitz, H.R. & Stern, M.J. An FGF receptor signaling pathway is required for the normal cell migrations of the sex myoblasts in *C. elegans* hermaphrodites. *Cell* **83**, 611–620 (1995).
- Kuroyanagi, H., Kobayashi, T., Mitani, S. & Hagiwara, M. Transgenic alternative-splicing reporters reveal tissue-specific expression profiles and regulation mechanisms *in vivo*. *Nat. Methods* **3**, 909–915 (2006).